Microbot Medical (FRA:CY9D) ROCE % : -260.88% (As of Sep. 2024)

View and export this data going back to . Start your Free Trial

What is Microbot Medical ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Microbot Medical's annualized ROCE % for the quarter that ended in Sep. 2024 was -260.88%.

Microbot Medical ROCE % Historical Data

The historical data trend for Microbot Medical's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Microbot Medical ROCE % Chart

Microbot Medical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-42.53

-30.15

-59.87

-126.01

-165.77

Microbot Medical Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROCE %	Get a 7-Day Free Trial															-121.05	-155.31	-178.04	-164.44	-260.88

Microbot Medical ROCE % Calculation

Microbot Medical's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-9.295	/	( ( (9.003 - 1.953)	+	(7.636 - 3.472) )	/ 2 )
	=	-9.295	/	( (7.05	+	4.164)	/ 2 )
	=	-9.295	/	5.607
	=	-165.77 %

Microbot Medical's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	-11.892	/	( ( (6.906 - 1.246)	+	(4.692 - 1.235) )	/ 2 )
	=	-11.892	/	( ( 5.66	+	3.457 )	/ 2 )
	=	-11.892	/	4.5585
	=	-260.88 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

Microbot Medical (FRA:CY9D) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Microbot Medical ROCE % Related Terms

Thank you for viewing the detailed overview of Microbot Medical's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Microbot Medical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Microbot Medical Inc (FRA:CY9D) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

MBOT:USA

Address

288 Grove Street, Suite 388, Braintree, MA, USA, 02184

Website

https://microbotmedical.com

Microbot Medical Inc is a pre-clinical medical device company. It specializes in developing next-generation micro-robotic medical technologies that can change the future of medicine. Their vision is to improve the quality of life of millions of patients globally by advancing micro-robotic technologies to perform surgical procedures and offer physicians and their patients less invasive and more precise solutions. The company's innovative platforms LIBERTY and Self-Cleaning Shunt (SCS) are in one of the fastest-growing segments in healthcare. The group continuously develops its technology with the goal to improve surgical outcomes worldwide. The firm presently holds domestic and global patents that strengthen its product portfolio and create barriers of entry.

Microbot Medical Headlines

No Headlines